Saima Usmani
Neurology · Newark, NJNPI 1669933800
Payments from drug & device makers
Across 96 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$212
- Eisai Inc.$181
- UCB, Inc.$132
- Teva Pharmaceuticals USA, Inc.$114
- Biogen$114
- Lilly USA, LLC$89
- plus $757 from 19 others
What the payments were for
- Food & beverage$1,598100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $212 |
| Eisai Inc. | 15 | $181 |
| UCB, Inc. | 7 | $132 |
| Teva Pharmaceuticals USA, Inc. | 7 | $114 |
| Biogen | 5 | $114 |
| Lilly USA, LLC | 4 | $89 |
| Neurocrine Biosciences, Inc. | 4 | $80 |
| Novartis | 4 | $77 |
| Alnylam Pharmaceuticals Inc. | 4 | $73 |
| Neurelis, Inc. | 4 | $69 |
| Argenx US, Inc. | 4 | $68 |
| SK Life Science, Inc. | 3 | $59 |
| AstraZeneca | 3 | $56 |
| Lundbeck LLC | 3 | $53 |
| Pfizer | 2 | $35 |
| Amgen | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Life Molecular Imaging Ltd | 1 | $14 |
How this compares
$1,598 in reported general payments places this provider in the 45th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 39 | $856 |
| Donepezil Hcl | 15 | $258 |
| Gabapentin | 16 | $153 |
Paid to pharmacies, not to this prescriber.
Other neurology in Newark
- Machteld HillenNewark$999K
- Priyank KhandelwalNewark$140K
- Nizar SouayahNewark$134K
- Mary Ann PiconeTeaneck$2.8M
- Steven BromleyAudubon$1.7M
- David DuncanNeptune$1.5M
- Lana Zhovtis RyersonNeptune$1.3M
- Amos KatzEatontown$1.2M
- Fiona GuptaOradell$1.1M
- Andrew SylvesterBridgewater$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.